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A cell-based phenotypic screen for inhibitors of bioﬁlm formation
in mycobacteria identiﬁed the small molecule TCA1, which has bac-
tericidal activity against both drug-susceptible and -resistant My-
cobacterium tuberculosis (Mtb) and sterilizesMtb in vitro combined
with rifampicin or isoniazid. In addition, TCA1 has bactericidal ac-
tivity against nonreplicatingMtb in vitro and is efﬁcacious in acute
and chronicMtb infection mouse models both alone and combined
with rifampicin or isoniazid. Transcriptional analysis revealed that
TCA1 down-regulates genes known to be involved in Mtb persis-
tence. Genetic and afﬁnity-based methods identiﬁed decaprenyl-
phosphoryl-β-D-ribofuranose oxidoreductase DprE1 and MoeW,
enzymes involved in cell wall andmolybdenum cofactor biosynthe-
sis, respectively, as targets responsible for the activity of TCA1.
These in vitro and in vivo results indicate that this compound func-
tions by a unique mechanism and suggest that TCA1 may lead to
the development of a class of antituberculosis agents.
drug resistance | dual mechanism
One of the greatest needs in global health is the developmentof new drugs against tuberculosis (TB) that shorten the
duration of TB chemotherapy and that are potent against drug-
resistant strains of Mycobacterium tuberculosis (Mtb), for which
current therapies are no longer effective (1). TB is exceptional
among bacterial infections in that even drug-susceptible strains
are difﬁcult to treat rapidly and effectively. This challenge is, in part,
because of the phenomenon of Mtb persistence, a state of pheno-
typic drug tolerance that is attributed to a quiescent or non-
replicating population of bacilli. Long treatment regimes make
compliance problematic and lead to the emergence of drug-
resistant mutants. Indeed, multidrug-resistant (MDR) and exten-
sively drug-resistant (XDR) Mtb strains are becoming widespread,
resulting in high failure rates, despite the use of second- and third-
line antibiotics and longer treatment times (up to 2 y). A new drug
in the drug regimen should shorten chemotherapy and overcome
the emergence of resistance to have a real impact on TB.
Although numerous cell-based screens against Mtb have been
performed, to date, most screens are designed to identify mole-
cules that are active against rapidly growing mycobacteria under
growth-optimal laboratory conditions and inherently biased to
identifying bactericidal or bacteriostatic compounds against rep-
licatingMtb (2). However, it is becoming apparent that the culture
conditions used in a screen very much affect our ability to identify
inhibitors that will be active in vivo (2, 3). This issue is a particular
concern in the development of drugs targeting persistent Mtb.
Both target- and cell-based screens have been carried out under
conditions that are thought to simulate those Mtb encounters
during a chronic infection (4, 5). For example, it has been shown
that oxygen deprivation or nutrient starvation in Mtb cultures
triggers metabolic changes, resulting in nonreplicating, pheno-
typically drug-resistant bacilli in vitro (6, 7). Indeed, anaerobic
Mtb cultures are resistant to isoniazid (INH) and partly resistant
to rifampicin (RIF) but highly sensitive to pyrazinamide (8),
underscoring the differing drug sensitivities of Mtb in different
metabolic states. Given the lack of clear consensus on cell culture
conditions that best reﬂect the in vivo biology of Mtb, we carried
out a screen based on in vitro bioﬁlm formation in the hope of
identifying compounds with new mechanisms of action that may
be effective against drug-resistant and -persistent Mtb. Here, we
report that the molecule TCA1 identiﬁed through this screen not
only shows bactericidal activity against both replicating (WT and
drug resistant) and nonreplicating Mtb but also, is efﬁcacious in
acute and chronic Mtb infection mouse models both alone and
combined with INH or RIF. Moreover, genetic and biochemical
studies show that TCA1 functions by inhibiting two distinct bio-
synthetic pathways with concomitant down-regulation of genes
known to be involved in mycobacterial persistence.
Results and Discussion
High-Throughput Screen Under Bioﬁlm Culture Conditions. Patho-
genic Mtb is not conducive to high-throughput screens involving
automation, because these experiments would need to be carried
out in a biosafety level 3 facility. However, M. smegmatis, a sap-
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rophytic, nonpathogenic mycobacteria that also forms in vitro
bioﬁlms (9) that induce drug tolerance (10), is amenable to high-
throughput screening. Therefore, the primary cell-based screen
was based on the inhibition of bioﬁlm formation inM. smegmatis.
We found that the in vitro bioﬁlm, visualized as a pellicle that
grows at the air–liquid interface, covers the whole surface of the
well in a 384-well plate after formed, affording a high signal-to-
noise ratio for positive hits. A diverse library of 70,000 hetero-
cycles was screened (SI Materials and Methods), which afforded
17 compounds with minimum inhibitory concentrations (MIC50
values) of less than 10 μM in a bioﬁlm inhibition assay. Two
classes of compounds were identiﬁed: the ﬁrst class inhibits the
growth of mycobacteria under bioﬁlm culture conditions, whereas
the second class inhibits the formation of bioﬁlms without sig-
niﬁcant growth inhibition. These hit compounds from the primary
screen were then tested for their ability to inhibit in vitro bioﬁlm
growth in virulent Mtb H37Rv using a scaled-up 24-well assay as
previously described (11). Two compounds, C7 and TCA1, were
found to also inhibit bioﬁlm formation by Mtb H37Rv (Fig. 1A).
TCA1, which displayed potent inhibitory activity against Mtb
under both bioﬁlm and planktonic culture conditions, was se-
lected for additional studies.
In Vitro Bactericidal Activity. TCA1 shows selective inhibitory ac-
tivity against bacterial growth—it is inactive against Escherichia
coli, Staphylococcus aureus, and Pseudomonas aeruginosa, suggest-
ing that the target for its bactericidal activity is speciﬁc to the genus
Mycobacterium (Fig. 1B). Interestingly, the activities of TCA1
against M. smegmatis, M. bovis bacillus Calmette–Guérin, and Mtb
are 20- to 150-fold higher in bioﬁlm medium (MIC50 = 0.03, 0.04,
and 0.01 μg/mL, respectively) than 7H9 medium (MIC50 = 4.5, 3,
and 0.19 μg/mL, respectively). This observation underscores the
variable efﬁcacy of a drug in different growth media (3), which in
part, may result from the expression of distinct target genes and
metabolic pathways. TCA1 is bactericidal with an MIC99 values of
2.1 μg/mL in solid medium. To evaluate the bactericidal activity of
TCA1 againstMtb compared with the two frontline TB drugs INH
and RIF, we performed a 21-d kinetic killing assay using compa-
rable levels of each of the three drugs (20× MIC50 of each of the
three drugs). TCA1 is active by itself against exponentially growing
virulentMtb in 7H9 media, with a more than 3 log reduction in the
number of bacilli over a treatment period of 21 d. Treatment with
INH or RIF resulted in a comparable drop in cfu over the ﬁrst 7 d
of treatment, but the subsequent outgrowth of bacilli detected in
INH- and RIF-treated cultures is absent in TCA1-treated cultures.
Furthermore, TCA1 combined with either RIF or INH is able to
sterilize an Mtb culture in ∼3 wk (Fig. 2A); removal of drug after
3 wk of combination drug treatment did not lead toMtb outgrowth.
We also tested the activity of TCA1 on drug-resistant Mtb.
RIF resistance is a marker for MDR-TB (90% of RIF-resistant
strains are also MDR) and typically requires 18–24 mo of
treatment. TCA1 by itself was active against a clinical strain that
is resistant to RIF (because of a mutation in rpoB), and more
importantly, combined with INH, it sterilized the cultures within 1
wk (Fig. 2B). Removal of both drugs after 3 wk of treatment did
not result in outgrowth. TCA1 was also found to be bactericidal
Fig. 1. Chemical structures of the afﬁnity resin (TCAP1) and the photo-afﬁnity probe (TCAP2) used in pull-down experiments. Hit compound from screen
under bioﬁlm culture condition. (A) Chemical structure of active compound. (B) TCA1 has selective activity against mycobacteria. (C) Chemical structures of
the afﬁnity resin and the photo-afﬁnity probe used in pull-down experiments.
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against a strain with a mutation in katG (resulting in resistance to
INH) (Fig. 2C). Finally, we also tested TCA1 against an XDR-TB
strain, mc28013, which is resistant to 10 TB drugs, including all
frontline drugs (Table S1). TCA1 showed potent bactericidal
activity against the XDR-TB strain (5 log cfu reduction in 3 wk)
(Fig. 2D). The lack of cross-resistance to TCA1 in any of these
drug-resistant strains suggests that TCA1 functions by a dis-
tinct mechanism.
We next tested the activity of TCA1 against nonreplicating
Mtb in a nutrient starvation assay, a widely used in vitro model of
the Mtb dormancy phenotype (12, 13). Under these conditions,
Mtb enters a nonreplicating state and has been shown to become
tolerant to drugs without acquiring heritable drug resistance-
inducing mutations (13). TCA1 shows bactericidal activity against
nonreplicatingMtb at a concentration of 7.5 μg/mL (40×MIC50 in
7H9 medium), reducing cfu by 3 logs in 3 wk (Fig. 2E). Under the
same assay conditions, RIF (40× MIC50 in 7H9 medium) showed
less bactericidal activity than TCA1. We also tested the activity of
TCA1 in an intramacrophage cell culture system to determine
whether it is active against intracellular mycobacteria, because in
the mouse model of infection and in humans, Mtb is believed to
reside mainly in macrophages. TCA1 was found to be quite potent
in an intracellular cfu assay with an MIC50 value of 0.6 μg/mL
[MIC50 (RIF) = 2.7 μg/mL, MIC50 (INH) = 0.2 μg/mL] (SI
Materials and Methods). Finally, TCA1 shows no cytotoxicity
against ﬁve mammalian cell lines (Huh7, 293T, K562, HepG2,
and Vero cells) at the highest concentration tested (100 μM for
Vero cells and 25 μM for others); an hERG assay indicated that
TCA1 has no activity at 30 μM (Tables S2 and S3).
TCA1 Is Efﬁcacious in Acute and Chronic Mtb Infection Mouse Models.
We next examined the activity of TCA1 in a mouse model ofMtb
infection. We ﬁrst determined the physical and pharmacokinetic
characteristics of TCA1. It is stable to proteolytic activity in hu-
man or mouse plasma for up to 4 h. Moreover, a GSH trapping
assay indicated that no GSH adduct was formed, and TCA1 has
no inhibitory activity against four CYP enzymes. After i.v. ad-
ministration, TCA1 exhibited a low clearance and steady-state
volume of distribution, with an elimination half-life of 0.73 h.
After oral administration of 20 and 50 mg/kg in solution formu-
lation, TCA1 showed a high Cmax (2,122 and 5,653 nM, re-
spectively), moderate exposure with oral bioavailability ranging
from 19% to 46%, and a half-life of 1.8 h (Tables S2 and S3).
We ﬁrst performed the in vivo efﬁcacy experiments in an
acute infection model with a low dose of TCA1. BALB/c mice
were infected with a low dose of Mtb H37Rv (∼200 bacilli);
2 wk after infection, mice were treated with TCA1 (40 mg/kg),
INH (25 mg/kg), or RIF (10 mg/kg) for 4 wk (dosed 1 time/d for
5 d/wk). The doses of INH andRIF are consistent with those doses
published in the literature (14). After 4 wk of treatment with
TCA1, the cfu dropped 0.5 log in lung and 1.5 logs in spleen, which
is comparable with the potency of RIF but less than the potency of
INH (Fig. S1). The gross pathology and histopathology also
showed signiﬁcant improvement in both tissues (Table S4). We
also tested the in vivo efﬁcacy of TCA1 (40 mg/kg) combined with
INH (25 mg/kg) or RIF (10 mg/kg). In the acute infection model,
TCA1+INH and TCA1+RIF showed nearly a 2 and 3 log cfu
reduction in lung, respectively, and amore than 3 log cfu reduction
in spleen (Fig. 3 A and B). There is a greater cfu drop in the lungs
of mice treated by the combination of TCA1 and INH relative to
Fig. 2. In vitro activity of TCA1. (A) Kill kinetics of Mtb by TCA1 (3.75 μg/mL) alone or combined with INH (1 μg/mL) or RIF (2 μg/mL) compared with RIF
(2 μg/mL) and INH (1 μg/mL) alone in 7H9 medium. Activity of TCA1 (3.75 μg/mL) against (B) an RIF-resistant Mtb strain and (C) an INH-resistant Mtb strain in
7H9 medium. (D) Kill kinetics of an XDR-TB strain by TCA1 (7.5 μg/mL) in 7H9 medium. (E) Activity of TCA1 against nonreplicating Mtb under nutrient
starvation conditions. (F) Quantitative PCR analysis of expression ratios of selected genes from TCA1-treated (3.75 μg/mL) and -untreated (0.1% DMSO) Mtb.
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the combination of INH and RIF. We next tested the drug in
a mouse model of chronic TB infection. Mice were challenged
with a low-dose aerosol infection, and treatment was initiated 4 wk
after infection. Similar combination treatments were efﬁcacious in
the chronic infection model as well (Fig. 3 C and D).
Because the mice were able to tolerate 40 mg/kg TCA1, we
increased the dose to 100 mg/kg using a similar protocol in the
acute infection model. After 4 wk, the cfu dropped nearly 2 logs
in lungs and more than 3 logs in spleen, showing that the in vivo
bactericidal activity of TCA1 is dose-dependent (Fig. 3 A and B).
The mice again showed no obvious adverse effects or weight loss
after 4 wk of treatment. We also tested the drug in the chronic
infection model at 100 mg/kg. Again, TCA1 showed efﬁcacy in
both lung (1 log cfu reduction) and spleen (1.4 log cfu reduction)
(Fig. 3 C and D). These results show that the in vitro efﬁcacy of
TCA1 is recapitulated in vivo, suggesting that the in vitro myco-
bacterial bioﬁlm is a useful phenotype to identify compounds ef-
fective against Mtb in vivo either alone or combined with existing
TB drugs.
Mechanism of Action Studies of TCA1. To gain insight into the
mechanism of action of TCA1, we treatedMtbH37Rv with TCA1
(3.75 μg/mL) in 7H9 media and carried out genome-wide tran-
scriptional analysis. Similar to INH and ethambutol (15), cell
wall and fatty acid biosynthetic genes are affected by TCA1
treatment, suggesting that TCA1 likely interferes with these path-
ways. Unlike other known TB drugs, 10 of 86 genes differentially
down-regulated compared with the DMSO control are genes pre-
viously implicated in TB dormancy, stress response, and RIF sus-
ceptibility. These genes include rv3130c–rv3134c, fdxA, and hspX
(members of the dos regulon), cysD, and rv3288c–rv3290c (mem-
bers of the sigF regulon). The microarray results were conﬁrmed
by quantitative PCR (Fig. 2F). Most of these genes are part of the
dormancy regulon controlled by dosR (16) and up-regulated under
hypoxic conditions or by nitric oxide exposure. For example,
fdxA, a low-redox potential electron carrier, is highly up-regulated
in Mtb under hypoxic conditions (17) but signiﬁcantly down-
regulated (>20-fold) in response to TCA1 treatment. Likewise,
rv3130c is induced (>300-fold) under multiple stress condi-
tions (18) but down-regulated (>30-fold) by TCA1. This down-
regulation of genes involved in dormancy and drug tolerance
seems to be unique to TCA1 and suggests that TCA1 may po-
tentially sensitize Mtb to killing by antibiotics.
To further explore the mechanism of action of TCA1, a
TCA1-resistant mutant that carries the cosmid (MSMEG_6379–
MSMEG_6384) was isolated by selection of M. smegmatis trans-
formed with a genomic cosmid library and grown in bioﬁlm
formation medium. Overexpression of each gene in this cosmid
revealed that MSMEG_6382, which is homologous to rv3790
in the Mtb genome, confers high-level resistance to TCA1 (>20×
MIC50) in both M. smegmatis and Mtb. We also managed to
isolate spontaneous resistant mutants of M. smegmatis and Mtb,
although the spontaneous mutation rate to TCA1 resistance is
extremely low (10−8 to 10−9). Whole-genome sequencing of the
genomic DNA of the resistant mutants revealed that they all have
Fig. 3. In vivo efﬁcacy of TCA1 in mouse models. In an acuteMtb infection mouse model (2 wk infection) followed by 4 wk of drug treatment, TCA1 showed
signiﬁcant bactericidal activity in (A) lungs and (B) spleen both alone (100 mg/kg) and combined with (40 mg/kg) INH (25 mg/kg) or RIF (10 mg/kg). The low
activity of RIF as a monotherapy in this model is consistent with what has been observed in a previous study (14). In a chronic TB infection mouse model (4 wk
low-dose infection) followed by 4wk of drug treatment, TCA1 showed activity in (C) lungs and (D) spleen both alone (100mg/kg) and combinedwith (40mg/kg)
INH (25 mg/kg) or RIF (10 mg/kg; P value < 0.05). Mice were gavaged with TCA1 1 time/d for 5 d/wk. RIF and INH were administered in drinking water.
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a single-point mutation, resulting in the amino acid replacement
Tyr321Cys in MSMEG_6382 and Tyr314Cys in rv3790 (Fig. 4A).
Rv3790 encodes DprE1, a component of the essential decap-
renyl-phosphoryl-β-D-ribofuranose 2′-epimerase DprE1/DprE2
required for cell wall arabinan biosynthesis. Indeed, TCA1 sup-
pressed the activity of M. smegmatis DprE1 in membrane and
cell envelope enzymatic fractions in a dose-dependent manner
(Fig. 4B). DprE1 was previously identiﬁed as the target of the
benzothiazinones (BTZs) and a nitro-triazole molecule (3, 14).
Both scaffolds contain active nitro-moieties and are believed to
covalently modify Cys387 on activation. We performed a com-
petitive binding assay using a ﬂuorescently labeled BTZ analog.
TCA1 potently competed with BTZ in binding to DprE1, sug-
gesting that the binding site of TCA1 overlaps with BTZ (Fig.
S2). However, TCA1 does not have an active nitro-moiety, and
the Tyr314Cys mutant strain that is resistant to TCA1 is sensitive
to BTZ, suggesting that the binding mechanism of TCA1 is
different from these nitro-heterocycles.
To determine the molecular basis by which TCA1 inhibits
DprE1, we determined the crystal structure of the enzyme bound
to TCA1 (Table S5). The overall structure of the DprE1–TCA1
complex is largely unaltered compared with the structure of the
ligand-free protein with the same crystal symmetry (19). The
enzyme, which is structurally related to the vanillyl-alcohol oxi-
dase family of ﬂavoproteins (20), consists of an FAD binding and
a substrate binding domain, with the ﬂavin moiety of FAD posi-
tioned at the interface between the two domains (Fig. 4C, Left).
The substrate binding domain includes two disordered loop re-
gions (residues 269–283 and 316–330) that leave the active site
open and accessible for inhibitors. TCA1 binds in the central
cavity of the enzyme, adjacent to the isoalloxazine ring of FAD,
in a boomerang-like conformation, with the thiophene moiety
inserted deeply into the bottom of the active site (Fig. 4C, Right).
The benzothiazole ring is oriented roughly parallel to the iso-
alloxazine of FAD. Noncovalent interactions between TCA1 and
the enzyme are dominated by hydrophobic and van der Waals
interactions (Fig. 4C), with the ﬂavin contributing a large fraction
of the total contact surface. Polar contacts are sparse but include
the H bonds between the carboxamido group and thiazole ni-
trogen of TCA1 and Nζ of Lys418 (3.0 and 3.1 Å, respectively).
The carbamate moiety makes van der Waals interactions with
the phenyl ring of Tyr314, consistent with the observation that
Fig. 4. TCA1 is a DprE1 inhibitor. (A) Sequence alignment of DprE1 of M. smegmatis and Mtb. A Y321C (Y314C in Mtb) mutation was identiﬁed in both
M. smegmatis and Mtb strains resistant to TCA1. (B) Inhibition of DprE1 by TCA1 in the cell-free assay for decaprenylphosphoryl arabinose (DPA) production
analyzed by TLC and autoradiography. M. smegmatis membrane or cell envelope fractions were incubated with (Left) phospho-[14C]-ribose diphosphate and
25 μg/mL TCA1 or BTZ043 or (Right) TCA1 in a dose–response fashion. Both TCA1 and BTZ043 potently inhibit conversion of the substrate DPR to the product
DPA by DprE1/DprE2 epimerase. (C) Molecular surface ofMtb DprE1 with the FAD domain in light blue and the substrate binding domain in beige. The surface
areas in pale green andmagenta indicate the positions of (Left) Cys387 and Tyr314. (Right) Noncovalent contacts between TCA1 and DprE1 are shown. Residues
within a 4-Å radius of the inhibitor (violet) are shown as sticks, with FAD in yellow. Dashed lines indicate the shortest contacts (yellow, hydrophobic/van der
Waals; orange, polar) between the residues and the inhibitor. Trp230, located within 4 Å of the carbamate moiety of TCA1, has been omitted for clarity.
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substituting this tyrosine with cysteine renders DprE1 insensitive
to TCA1. Superimposition of the structures of DprE1 bound to
the BTZ analog (CT325) (19) and TCA1 showed that the binding
sites of these two inhibitors overlap signiﬁcantly.
The above results suggest that DprE1 is a relevant target for the
bactericidal activity of TCA1 against replicating bacteria, similar
to BTZ. However, there are some clear distinctions between
TCA1 and BTZ. First, BTZ is not active against nonreplicating
Mtb (14), whereas TCA1 is active against replicating and non-
replicating Mtb. Second, the gene expression proﬁles of Mtb
treated by two compounds are also very different—TCA1 down-
regulates persistence genes that are usually up-regulated in Mtb-
dormant models, whereas BTZ does not (14). The Mtb strain
overexpressing DprE1 is resistant to TCA1 in 7H9 medium but
still sensitive to TCA1 in the nutrient starvation model (Fig. 5A).
Moreover, TCA1 still potentiates INH or RIF on this DprE1-
overexpressing strain (Fig. 5B). These results suggest that TCA1
could potentially act on an additional mycobacterial target.
Because TCA1 had diminished activity against the DprE1
(Y314C) mutant in normal growth medium, it is possible that a
second TCA1 target is not essential for Mtb growth under con-
ditions of optimal growth. This complication makes the selection
of relevant mutants more difﬁcult, and therefore, afﬁnity-based
methods were used to identify additional potential targets. Among
a group of analogs of TCA1, we found that a pyridyl analog,
TCA17, has very similar in vitro activity to the activity of TCA1.
TCA17 was immobilized on a resin through a linker moiety
(TCAP1) (Fig. 1C) and used in a pull-down experiment with cell
lysates fromMtb. A 35-kDa band was identiﬁed on an SDS/PAGE
after silver staining, which disappeared in the presence of 50 μM
TCA1 as a competitor. MS identiﬁed the band asMoeW, a protein
involved in the biosynthesis of the molybdenum cofactor (MoCo)
(Fig. S3) with homologs in only a few bacterial genomes. To con-
ﬁrm the binding of TCA1 to MoeW, we overexpressed moeW in
E. coli (which lacks an moeW gene homolog in its genome) and
treated this strain with a photoafﬁnity probe analogous to TCA1
(TCAP2) (Fig. 1C) followed by UV irradiation and cell lysis. As
shown in Fig. S4, a band with the size of MoeW is present on an
SDS/PAGE gel for the sample from the moeW-induced strain and
absent in the uninduced control sample. These results show that
TCA1 scaffold directly binds to MoeW.
MoeW is predicted to contain an FAD/NAD binding domain
by protein sequence analysis, but its function has yet to be de-
termined. The gene encodingMoeW is only conserved inMtb and
bacillus Calmette–Guérin and not M. smegmatis or other myco-
bacterial species, although it is homologous to moeB, another
gene involved in MoCo biosynthesis pathway and conserved
in all mycobacteria species and many other bacteria (21). All
Fig. 5. TCA1 inhibits MoCo biosynthesis. (A) Mtb overexpressing dprE1 is sensitive to TCA1 (7.5 μg/mL) under nutrient starvation conditions. (B) Mtb
overexpressing dprE1 conferred resistance to TCA1 (3.75 μg/mL) in 7H9 medium. In the meantime, TCA1 acts synergistically with INH (1 μg/mL) or RIF (2 μg/mL)
against the same strain. (C–F) MoCo inhibition assay. HPLC proﬁles of MoCo Form A dephospho standard and sample extracted fromMtb. Arrow indicates the
position of MoCo Form A dephospho. (C) MoCo Form A dephospho standard from synthetic source. (D) Extracted sample fromMtb in the absence of TCA1. (E)
Extracted sample from Mtb after treatment with TCA1 (7.5 μg/mL; 18 h). (F) Extracted sample fromMtb in the absence of TCA1 spiked with an MoCo Form A
dephospho standard. (G) Kill kinetics of WTMtb andMtb overexpressingmoeW by 7.5 μg/mL TCA1 in media using nitrate as the only nitrogen source. (H) Kill
kinetics of WT Mtb and Mtb overexpressing moeW by 7.5 μg/mL TCA1 under nutrient starvation conditions.
6 of 8 | www.pnas.org/cgi/doi/10.1073/pnas.1309171110 Wang et al.
molybdenum-using enzymes identiﬁed to date contain MoCo.
MoCo is essential for the nitrate respiratory and assimilatory
function of Mtb nitro-reductase. Some of these nitro-reductases
have been found to be involved in the response ofMtb to hypoxia
and nitric oxide (21, 22). To determine if TCA1 can block the
biosynthesis of MoCo, we analyzed cell extracts fromMtb treated
with TCA1 by detection of dephosphorylated MoCo Form A
using HPLC with ﬂuorescence detection. Indeed, TCA1 (7.5 μg/
mL) completely abolished the formation of MoCo in Mtb (Fig. 5
C–F). It is known that MoCo is indispensable for nitrate assimi-
lation by Mtb and thus, essential for Mtb to survive in media that
uses nitrate as the only nitrogen source (designated as nitrate
media). We generated an Mtb strain overexpressing moeW and
found it to confer resistance to TCA1 in nitrate media over 30 d
of treatment (Fig. 5G). These results clearly show that TCA1
asserts its activity againstMtb by inhibition of MoCo biosynthesis
through interaction with MoeW. The Mtb strain overexpressing
moeW conferred resistance to TCA1 in a nutrient starvation
model over 21 d of treatment as well (Fig. 5H), but the lower level
of resistance to TCA1 in the nutrient starvation model than ni-
trate media suggests that the mechanism of action of TCA1 is
more complicated under the former condition. Nevertheless,
the biochemical and genetic results clearly show that MoeW is a
relevant target of TCA1.
Conclusion
We have developed a cell-based screen involving the growth of
mycobacteria as an in vitro bioﬁlm (a pellicle). The natural mode
of growth ofMtb in liquid culture in the absence of detergent is as
a pellicle at the liquid–air interface. Indeed, bacillus Calmette–
Guérin is grown as a pellicle for vaccine production. This assay
allowed us to identify a potent inhibitor TCA1 against both rep-
licating and nonreplicating Mtb as well as drug-resistant Mtb.
TCA1 functions by a unique mechanism involving down-regula-
tion of persistence genes and inhibition of both cell wall andMoCo
biosynthesis. Moreover, TCA1 showed excellent in vivo efﬁcacy in
both acute and chronic TB infection mouse models, suggesting
that this compound may serve as a lead for the development of
a class of drugs against persistent and drug-resistantMtb. Indeed,
we have subsequently identiﬁed a compound with good serum
half-life that has excellent activities under both aerobic and an-
aerobic conditions (MIC50 values are 0.3 and 1.5 μg/mL, respec-
tively). Future work will focus on additional improvements in the
in vivo activity of this molecule and detailed mechanistic studies,
including attempts to isolate additional resistant mutants under
varied growth conditions. This work underscores the power of
cell-based phenotypic screens to uncover molecules with mech-
anisms of action that provide unique approaches to the treatment
of human disease.
Materials and Methods
High-Throughput Screen for Inhibitors of Bioﬁlm Formation Inhibition. A di-
verse chemical library (∼70,000 compounds) was used for the primary screen.
This in-house compound library was created based on a chemoinformatic
analysis of scaffold chemical diversity, historical proprietary screen hit rates
[>300 Mio data points from the high throughput (HTS) database], and
commercial availability; 105/mL M. smegmatis cells were plated in 384-well
plates in bioﬁlm formation medium of M63 salts minimal medium supple-
mented with 2% glucose, 0.5% Casamino Acids, 1 mM MgSO4, and 0.7 mM
CaCl2. RIF and TMC207 were used as positive controls, and DMSO (0.1%) was
used as a negative control. Cells were treated with 10 μM compound and
incubated for 3 d, and the OD of each well was determined with an EnVision
Multilabel Reader. The average Z′ and coefﬁcient values are 0.512 and 8.7%,
respectively. We used a high-stringency cutoff (threefold inhibition) to pick
hits that are most likely growth inhibitors (hit rate = 0.03%) and a low-
stringency cutoff (twofold inhibition) to include hits that inhibit bioﬁlm
formation without signiﬁcant growth inhibition (hit rate = 0.17%).
In Vitro Activity Assays. For kinetic killing assays, exponentially growing cul-
tures of mycobacteria were diluted in fresh media to an OD600 of 0.1–0.2.
Various drugs were added to the culture at the indicated concentrations. The
number of cfus at the start of the experiment was estimated by plating ap-
propriate dilutions of the culture onto 7H10 agar plates. The effect of drug
was monitored by plating for cfus at the indicated time points. All experi-
ments were carried out in triplicate. MICs were determined by a turbidity
assay. Threefold serial dilutions in DMSO were prepared for each compound.
Mtb cultures (OD = 0.04) were incubated with compounds at 37 °C for 5 d,
and OD600 was determined with an Envision plate reader. All experiments
were carried out in duplicate. For assays under starvation conditions, a log-
phase growing Mtb culture was centrifuged, and the cell pellet was washed
two times with PBS, resuspended in PBS with Tyloxapol (0.05%; OD = 0.3),
and incubated with DMSO, TCA1 (7.5 μg/mL), and RIF (2 μg/mL). All experi-
ments were carried out in triplicate. For intracellular macrophage assays,
J744.1 murine macrophage cells were infected with Mtb at a multiplicity of
infection (MOI) of 1:3 and incubated for 2 h at 37 °C. After washing the cell
monolayer three times, 20 μM amikacin was added, and the culture was in-
cubated for an additional 2 h to kill the remaining extracellular bacteria.
Infected cells were then incubated in the presence of serial dilutions of
compounds for 5 d. Cells were washed three times and lysed in each well;
the lysate was transferred to a 96-well plate for serial dilution and then
plated on 7H11 agar medium for cfu assays. All experiments were carried
out in triplicate.
In Vivo Efﬁcacy Experiments. Six- to eight-week-old female BALB/c mice (US
National Cancer Institute) were infected by aerosol with a low dose (∼50
bacilli) of Mtb H37Rv. Infection dose was veriﬁed by plating the inoculum
and the whole-lung homogenates onto 7H10 plates at 24 h postinfection.
Treatment of BALB/c mice began at either 2 or 4 wk postinfection, with RIF
(10 mg/kg) and INH (25 mg/kg) administered ad libitum in drinking water
(changed one time every 2 d). TCA1 was administered by oral gavage one
time daily for 5 d/wk at a dosage of either 40 or 100 mg/kg for the indicated
durations. At predetermined time points or humane endpoints, animals
were heavily sedated and euthanized, and tissues were collected for culture
and pathology. Treatment efﬁcacy was assessed on the basis of cfu in the
lungs and spleen of treated mice compared with untreated controls and
bacterial burden in these organs before treatment start. Organs were ho-
mogenized in PBS containing Tween-80 [0.05% (vol/vol)], and various dilu-
tions were placed on 7H10 plates. Plates were incubated at 37 °C for 3 wk,
and cfus on the various plates were recorded. All animal experimental
protocols were approved by the Animal Care and Use Committee of AECOM.
Genome-Wide Transcriptional Analysis. Triplicate 10-mL cultures of mycobac-
teria were grown to log phase for transcriptional proﬁling of planktonic cells
or for 3 wk in pellicle media for transcriptional proﬁling of pellicle cells. For
TCA1 treatment, log-phase cultures were treated with 3.75 μg/mL TCA1 or
DMSO vehicle for 12 h. Cells were harvested, washed, and resuspended in
1 mL RNA Protect reagent (Qiagen) and incubated 4 h at room temperature
(21 °C). All transcriptional proﬁling procedures, including RNA extraction,
DNase treatment, cDNA synthesis, labeling, microarray hybridization, wash-
ing, scanning, and data analysis, were performed as previously described (23).
Microarray data have been deposited in the US National Center for Bio-
technology Information Gene Expression Omnibus (accession no. GSE42151).
For quantitative PCR experiments, diluted cDNA was used as a template at
50 ng per reaction for real-time PCR reactions containing primer sets designed
by Primer 3 and SYBR Green PCRMasterMix (Applied Biosystems) in accordance
with the manufacturers’ instructions. These reactions were carried out on an
ABI 9700HT real-time PCR cycler (Applied Biosystems).
DprE1 Competition Assay. DprE1 was incubated with serial dilutions of TCA1
for 15 min. BTZ-BODIPY was added, and the sample was incubated for 1 h at
37 °C. BTZ-BODIPY is a ﬂuorescent BTZ derivative that reacts in the presence
of farnesylphosphoribose, with DprE1 forming a covalent bond. Samples are
then analyzed by SDS/PAGE (ﬂuorescence and Coomassie staining).
Crystallization and Structure Determination. Mtb DprE1 (Rv3790) was pre-
pared for crystallization as described in the work by Batt et al. (19). Before
setting up crystallization experiments, the TCA1 inhibitor (in DMSO) was in-
cubated with concentrated protein (∼35 mg/mL) for 30 min at a molar ratio
of 3 TCA1:1 DprE1. Crystals were grown by sitting drop vapor diffusion and
appeared over a reservoir consisting of 40–43% (wt/vol) polypropylene glycol
400 and 0.1 M imidazole, pH 7.0. Crystals were mounted into nylon loops
directly from the drop and frozen in liquid nitrogen. X-ray diffraction data
to 2.6 Å resolution were recorded on beamline I02 of the Diamond Light
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Source (Table S5). The crystals were in space group P21, with twomolecules of
the complex in the crystallographic asymmetric unit. Initial phases were
obtained by molecular replacement (PHASER) (24) using the apo structure
of DprE1 (Protein Data Bank ID code 4FDP) (19) as a search model. After
reﬁnement of the molecular replacement solution, density for TCA1 was
clearly visible in the active sites of the two crystallographically distinct
copies of DprE1. Density shape and stereochemical constraints allowed us to
unequivocally place the inhibitor in the active site of DprE1. Model re-
building and structure reﬁnement (COOT) (25), REFMAC5 (26), and PHENIX.
REFINE (27) led to ﬁnal R factors of 23.7% and 17.6% for the test and
working sets, respectively.
Afﬁnity-Based Proteomics and Photo-Afﬁnity Labeling. H37Ra cells were lysed
with homogenization buffer (60 mM β-glycerophosphate, 15 mM p-nitro-
phenyl phosphate, 25 mM Mops, pH 7.2, 15 mM MgCl2, 1 mM DTT, protease
inhibitors, 0.5% Nonidet P-40). Cell lysates were centrifuged at 16,000 × g
for 20 min at 4 °C, and the supernatant was collected. Total protein con-
centration in the supernatant was determined by a BCA protein assay kit
(Pierce). The lysates (1 mg) were then added to the afﬁnity resin (30 μL), and
the loading buffer (50 mM Tris·HCl, pH 7.4, 5 mM NaF, 250 mM NaCl, 5 mM
EDTA, 5 mM EGTA, protease inhibitors, 0.1% Nonidet P-40) was added to a
ﬁnal volume of 1 mL (for the competition experiment, TCA1 was added to
a ﬁnal concentration of 50 μM). After rotating at 4 °C for 1 h, the mixture
was centrifuged at 16,000 × g for 1 min at 4 °C, and the supernatant was
removed. The afﬁnity resin was then washed ﬁve times with cold loading
buffer and eluted by boiling with Laemmli sample buffer (Invitrogen) at
95 °C for 3 min. Samples were loaded and separated on a 4–20% Tris·glycine
gel (Invitrogen). The gel band was extracted and analyzed by proteomics.
For the photo-afﬁnity experiments, E. coli cells overexpressing MoeW and
native cells were lysed, and the photo-afﬁnity probe was added to cell
lysates (1 mg) in 50 μL PBS and incubated for 2 h at room temperature
followed by UV irradiation with a UV lamp for 20 min. The reaction mixtures
were then subjected to click chemistry with rhodamine-azide (100 μM) and
incubated for 2 h at room temperature with gentle mixing. The reactions
were terminated by the addition of prechilled acetone (0.5 mL), placed
at −20 °C for 30 min, and centrifuged at 16,000 × g for 10 min at 4 °C to
precipitate proteins. The pellet was washed two times with 200 μL pre-
chilled methanol, resuspended in 25 μL 1× standard reducing SDS loading
buffer, and heated for 10 min at 95 °C; samples were loaded for sepa-
ration by SDS/PAGE and then visualized by in-gel ﬂuorescent scanning.
In Vitro Assays in Nitrate-Only Media. AnMtb culture was resuspended under
nitrogen-limiting conditions (22) (a basal medium [1 L basal medium con-
tains 1 g KH2PO4, 2.5 g Na2HPO4, 2 g K2SO4, 2 mL trace elements; 1 L trace
elements contained 40 mg ZnCl2, 200 mg FeCl30.6H2O, 10 mg CuCl20.4H2O,
10 mg MnCl20.4H2O, 10 mg Na2B4O70.10H2O, 10 mg (NH4)6Mo7O240.4H2O]
supplemented with NaNO3 as the sole source of nitrogen, 0.5 mM MgCl2,
0.5 mM CaCl2, 10% ADS, 0.2% glycerol and 0.05% Tween 80) and incubated
for 24 h; 7.5 μg/mL TCA1 was then added to the culture and incubated for
30 d. Cfu assay was used to determine the bacterial viability at each time point.
All experiments were carried out in triplicate.
MoCo Inhibition Assay. The synthesis of MoCo Form A dephospho was carried
out according to the procedures described. The 1H-NMR spectrum matches
what has been reported in the literature (28, 29). Conversion of all sources of
molybdopterin to Form A dephospho was performed by the methods pre-
viously reported with slight modiﬁcations (21, 30); 100 mL Mtb culture were
harvested, and the pellet was resuspended in extraction solution (2 mL;
10 mM sodium ascorbate). The cells were lysed and centrifuged at 16,000 × g;
the supernatant was collected and treated with acidic iodine solution at 95 °C
for 25 min, and the excess iodine was removed by adding sodium ascorbate.
After centrifugation, the solution was neutralized with ammonium hydroxide
and then concentrated and dephosphorylated using calf intestinal phosphatase
(NEB) at 37 °C for 3 h. HPLC analysis was performed using Agilent C18 column
(150 × 4.6 mm, 10-μm particle size) with gradient elution by buffer A (50 mM
ammonium acetate) and buffer B (MeOH; 97% A to 93% A in 14 min and 97%
B wash from 15 to 22 min). Fluorescence detection was at 370/450 nm.
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